Health Condition 1: C34- Malignant neoplasm of bronchus andlung
Conditions
Interventions
Intervention1: AI based platform- OncoPredikt: The AI-based platform, OncoPredikt, predicts molecular and gene mutation status from H&E-stained digital slides and correlates these findings with outcom
Sponsors
OneCell Diagnostic India Pvt. Ltd
Bhaktivedanta Hospital and Research Institute
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients whose NGS (conventional testing) reports are available with confirmed diagnosis of Lung cancer with or without mutation status in the listed genes. (KRAS, BRAF, EGFR, RET, ALK, ROS1, MET, STK11, ERBB2, NTRK mutations). 2. Patients whose Lung biopsy H&E slides or tissue biopsy slide is available. 3. Patients who would be willing to participate voluntarily.
Exclusion criteria
Exclusion criteria: Patients who do not have lung adenocarcinoma with a biomarker.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OncoPredikt-based prediction of lung panel gene signature mutation status can be accurately performed on diagnostic H&E slides potentially yielding results quickly and affordably, even when limited tissue is available for testing, thus, providing a reliable and accurate screening tool to predict lung panel gene mutations. Timepoint: 15 days | — |
Secondary
| Measure | Time frame |
|---|---|
| NilTimepoint: Nil | — |
Countries
India
Contacts
Public ContactDr Nirmal Raut
Bhaktivedanta Hospital and Research Institute
Outcome results
None listed